NCT03095040 - CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter

Enrollment

390

Participants

Timeline

Start Date

December 16, 2016

Primary Completion Date

February 28, 2021

Study Completion Date

December 31, 2021

Conditions

Renal Cell Cancer Metastatic

Interventions

DRUG

CM082 combined with everolimus

CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles

DRUG

CM082

CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles

DRUG

Everolimus

Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing